

# Drug Policy:

## Kymriah™ (tisagenlecleucel)

<b>POLICY NUMBER</b> UM ONC_1324	<b>SUBJECT</b> Kymriah™ (tisagenlecleucel)		<b>DEPT/PROGRAM</b> UM Dept	<b>PAGE 1 of 3</b>
<b>DATES COMMITTEE REVIEWED</b> 09/13/17, 09/21/18, 08/14/19, 12/11/19, 06/10/20, 02/10/21, 05/12/21, 11/15/21, 02/09/22, 05/11/22, 09/14/22, 04/12/23, 02/14/24	<b>APPROVAL DATE</b> February 14, 2024	<b>EFFECTIVE DATE</b> February 23, 2024	<b>COMMITTEE APPROVAL DATES</b> 09/13/17, 09/21/18, 08/14/19, 12/11/19, 06/10/20, 02/10/21, 05/12/21, 11/15/21, 02/09/22, 05/11/22, 09/14/22, 04/12/23, 02/14/24	
<b>PRIMARY BUSINESS OWNER: UM</b>		<b>COMMITTEE/BOARD APPROVAL</b> Utilization Management Committee		
<b>NCQA STANDARDS</b> UM 2		<b>ADDITIONAL AREAS OF IMPACT</b>		
<b>CMS REQUIREMENTS</b>	<b>STATE/FEDERAL REQUIREMENTS</b>		<b>APPLICABLE LINES OF BUSINESS</b> Commercial, Exchange, Medicaid	

### I. PURPOSE

To define and describe the accepted indications for Kymriah (tisagenlecleucel) usage in the treatment of cancer, including FDA approved indications, and off-label indications.

Evolent is responsible for processing all medication requests from network ordering providers. Medications not authorized by Evolent may be deemed as not approvable and therefore not reimbursable.

The use of this drug must be supported by one of the following: FDA approved product labeling, CMS-approved compendia, National Comprehensive Cancer Network (NCCN), American Society of Clinical Oncology (ASCO) clinical guidelines, or peer-reviewed literature that meets the requirements of the CMS Medicare Benefit Policy Manual Chapter 15.

### II. INDICATIONS FOR USE/INCLUSION CRITERIA

#### A. Continuation requests for a not-approvable medication shall be exempt from this Evolent policy provided:

1. The requested medication was used within the last year, **AND**
2. The member has not experienced disease progression and/or no intolerance to the requested medication, **AND**
3. Additional medication(s) are not being added to the continuation request.

#### B. Acute Lymphoblastic Leukemia (ALL)

1. Kymriah (tisagenlecleucel) is being used when the following criteria are met:
  - a. Member is 25 years old or younger, and has Acute Lymphoblastic Leukemia with confirmed documentation of CD19 tumor expression (demonstrated in bone marrow or peripheral blood by flow cytometry) **AND**

- b. Member has B-Cell ALL that is refractory or in second or later relapse.

### C. B-Cell Lymphomas

- 1. Kymriah (tisagenlecleucel) may be used for members who are 18 years of age or older with relapsed or refractory large B-cell lymphoma after two or more lines of systemic therapy, including diffuse large B-cell lymphoma (DLBCL) not otherwise specified, high grade B-cell lymphoma and DLBCL arising from follicular lymphoma.

## III. EXCLUSION CRITERIA

- A. Kymriah (tisagenlecleucel) is being used after disease progression on or after the same regimen or another CAR-T cell therapy directed towards CD19 antigen [Breyanzi (lisocabtagene maraleucel), Tecartus (brexucabtagene autoleucel), or Yescarta (axicabtagene ciloleucel)].
- B. CD-19 positivity not confirmed and documented.
- C. Active CNS involvement with lymphoma.
- D. Dosing exceeds single dose limit of Kymriah (tisagenlecleucel)  $6.0 \times 10^8$  CAR-positive viable T cells (for B-Cell Lymphomas);  $2.5 \times 10^8$  CAR-positive viable T cells (for ALL).
- E. Does not exceed duration limit as one time administration.
- F. Investigational use of Kymriah (tisagenlecleucel) with an off-label indication that is not sufficient in evidence or is not generally accepted by the medical community. Sufficient evidence that is not supported by CMS recognized compendia or acceptable peer reviewed literature is defined as any of the following:
  - 1. Whether the clinical characteristics of the patient and the cancer are adequately represented in the published evidence.
  - 2. Whether the administered chemotherapy/biologic therapy/immune therapy/targeted therapy/other oncologic therapy regimen is adequately represented in the published evidence.
  - 3. Whether the reported study outcomes represent clinically meaningful outcomes experienced by patients. Generally, the definition of Clinically Meaningful outcomes are those recommended by ASCO, e.g., Hazard Ratio of less than 0.80 and the recommended survival benefit for OS and PFS should be at least 3 months.
  - 4. Whether the experimental design, considering the drugs and conditions under investigation, is appropriate to address the investigative question. (For example, in some clinical studies, it may be unnecessary or not feasible to use randomization, double blind trials, placebos, or crossover).
  - 5. That non-randomized clinical trials with a significant number of subjects may be a basis for supportive clinical evidence for determining accepted uses of drugs.
  - 6. That case reports are generally considered uncontrolled and anecdotal information and do not provide adequate supportive clinical evidence for determining accepted uses of drugs.
  - 7. That abstracts (including meeting abstracts) without the full article from the approved peer-reviewed journals lack supporting clinical evidence for determining accepted uses of drugs.

## IV. MEDICATION MANAGEMENT

- A. Please refer to the FDA label/package insert for details regarding these topics.

## V. APPROVAL AUTHORITY

- A. Review – Utilization Management Department
- B. Final Approval – Utilization Management Committee

## VI. ATTACHMENTS

- A. None

## VII. REFERENCES

- A. Fowler NH, et al. Tisagenlecleucel in adult relapsed or refractory follicular lymphoma: the phase 2 ELARA trial. *Nat Med.* 2022 Feb;28(2):325-332.
- B. Schuster SJ, et al. JULIET Trial. Tisagenlecleucel in Adult Relapsed or Refractory Diffuse Large B-Cell Lymphoma. *N Engl J Med.* 2019 Jan 3;380(1):45-56.
- C. Maude SL, et al. CART19 Trial. Chimeric antigen receptor T cells for sustained remissions in leukemia. *N Engl J Med.* 2014 Oct 16;371(16):1507-17.
- D. Kymriah prescribing information. Novartis Pharmaceuticals Corporation. East Hanover, NJ 2022.
- E. Ellis LM, et al. American Society of Clinical Oncology perspective: Raising the bar for clinical trials by defining clinically meaningful outcomes. *J Clin Oncol.* 2014 Apr 20;32(12):1277-80.
- F. Medicare Benefit Policy Manual Chapter 15 Covered Medical and Other Health Services:  
<https://www.cms.gov/Regulations-and-Guidance/Guidance/Manuals/Downloads/bp102c15.pdf>.